cholangiocarcinoma
FDA Approves Tibsovo for Adjuvant Treatment of IDH1-Mutated UC
The FDA approved ivosidenib (Tibsovo, Servier) for adults with previously treated, locally advanced or metastatic ...
AUGUST 30, 2021
Survey Cites Cholangiocarcinoma Mutation Confusion
Oncologists could use some education about testing for and targeting the major mutations in cholangiocarcinoma, ...
JUNE 15, 2021
FDA Approves Truseltiq for Some Advanced Cholangiocarcinoma Patients
The FDA granted accelerated approval to infigratinib (Truseltiq, QED Therapeutics) for the treatment of adults with ...
JUNE 4, 2021
Breakthrough Therapy for Advanced Cholangiocarcinoma Approved
The FDA granted accelerated approval to pemigatinib (Pemazyre, Incyte Corporation), the first treatment approved ...
APRIL 20, 2020
Load more